Our ADS shares began trading on February 5, 2021.
The initial public offering price was US $10.
Our ADS shares are listed on the NASDAQ Capital Market under the ticker symbol EVAX.
An American depositary share (ADS) is the U.S. dollar-denominated equity share of a foreign-based company available for purchase on an American stock exchange.
Each ADS is a tradeable security representing one of the Company’s Ordinary Shares. The ADSs have been approved for trading on the NASDAQ Capital Market under the ticker symbol EVAX
The Bank of New York Mellon, Inc.(“BNY Mellon’) acts as Depositary for the Depositary Receipt ("DR") program of Evaxion Biotech A/S, pursuant to a deposit agreement among BNY Mellon and Evaxion Biotech A/S.
Evaxion has never declared or paid any cash dividends and does not anticipate doing so in the foreseeable future. The company intends to retain all attainable funds to fund the development of its business.
Dirch Passers Allé 36
2000 Frederiksberg
Denmark
Duane Morris LLP, New York, New York is Evaxion’s US legal counsel. Mazanti-Andersen, Copenhagen, Denmark is Evaxion’s Danish legal counsel.
Our financial reports are available at: https://evaxion-biotech.com/investors/reports-and-presentations/quarterly-reports
Evaxion Board Diversity Matrix (As of August 8, 2022) |
|||
Gender |
Female |
Male |
Non-binary |
Total Directors |
1 |
4 |
0 |
Number of Directors who identify in any of the categories below: |
|||
African American or Black |
0 |
0 |
0 |
Alaskan Native or Native American |
0 |
0 |
0 |
Asian |
0 |
0 |
0 |
Hispanic or Latinx |
0 |
0 |
0 |
Native Hawaiian or Pacific Islander |
0 |
0 |
0 |
White |
0 |
0 |
0 |
Two or more races or ethnicities |
0 |
0 |
0 |
LGBTQ+ |
0 |
0 |
0 |
Did not disclose demographic background |
5 |